For the Inventor, By the Inventor

Enter assignee name

Pembroke, Bermuda

Celgene Car LLC

USPTO Granted Patents = 44

CIPO Patents = 6

EPO Patents = 10

Forward Citations = 232

Loading Chart...

Loading Chart...

53 inventors (with patents filed for the assignee):

Deqiang Niu (29 out of 83 patents)

Juswinder Singh (28 out of 68 patents)

Russell Colyn Petter (28 out of 81 patents)

4. Lixin Qiao (13 out of 40 patents)

5. Joseph John McDonald (12 out of 14 patents)

6. Zhendong Zhu (12 out of 20 patents)

7. Hormoz Mazdiyasni (11 out of 19 patents)

8. Kwangho Lee (10 out of 27 patents)

9. Richland Wayne Tester (9 out of 30 patents)

10. John Malona (9 out of 11 patents)

11. Arthur F Kluge (8 out of 95 patents)

12. Alexander L Ruchelman (6 out of 56 patents)

13. William Frederick Westlin, Iii (6 out of 15 patents)

14. Yike Ni (6 out of 7 patents)

15. Chittari Pabba (6 out of 8 patents)

Core Competencies:

MK2 Inhibitors

Protein Kinase Inhibitors

Heteroaryl Compounds

EGFR Kinase Inhibitors

ERK Inhibitors

Pyrimidines

Covalent Modification

Deuterated Analogs

Heterocyclic Compounds

BTK Inhibitors

HCV Protease Inhibitors

Substituted Pyrido Compounds

44 patents: Sort by Forward Citations

1. 11655257 - MK2 inhibitors, synthesis thereof, and intermediates thereto (2023-05-23),

2. 11629153 - Forms and compositions of a MK2 inhibitor (2023-04-18),

3. 11584757 - MK2 inhibitors and uses thereof (2023-02-21),

4. 11542492 - Ligand-directed covalent modification of protein (2023-01-03),

5. 11351168 - 2,4-disubstituted pyrimidines useful as kinase inhibitors (2022-06-07),

6. 11292772 - Salts of an epidermal growth factor receptor kinase inhibitor (2022-04-05),

7. 11230551 - Deuterated analogs of MK2 inhibitors and uses thereof (2022-01-25),

8. 11124525 - Heteroaryl compounds useful as MK2 inhibitors (2021-09-21),

9. 11098061 - MK2 inhibitors and uses thereof (2021-08-24),

10. 11098057 - 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof (2021-08-24),

11. 11096942 - Heterocyclic compounds and uses thereof (2021-08-24),

12. 10946016 - Solid forms of an epidermal growth factor receptor kinase inhibitor (2021-03-16),

13. 10894796 - MK2 inhibitors, synthesis thereof, and intermediates thereto (2021-01-19),

14. 10882867 - Forms and compositions of a MK2 inhibitor (2021-01-05),

15. 10828300 - Substituted 2,4-diaminopyrimidines as kinase inhibitors (2020-11-10),

Celgene CAR LLC is a leading biopharmaceutical company dedicated to discovering, developing, and delivering innovative therapies for patients worldwide. With a focus on cancer and other serious diseases, Celgene CAR LLC utilizes cutting-edge technologies, including chimeric antigen receptor (CAR) T-cell therapy, to provide groundbreaking treatments. Through collaborative partnerships and a commitment to scientific excellence, Celgene CAR LLC aims to improve patients' lives and advance the field of biotechnology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

44 Patents

#1 in Pembroke

#17 in Bermuda

#15,298 in the World

Pembroke, Bermuda

Celgene Car LLC

Forward Citations = 232

53 inventors:

Deqiang Niu (29 out of 83 patents)

Juswinder Singh (28 out of 68 patents)

Russell Colyn Petter (28 out of 81 patents)

4. Lixin Qiao (13 out of 40 patents)

5. Joseph John McDonald (12 out of 14 patents)

Please report any incorrect information to support@idiyas.com

Loading…